MHC Class II-Mediated Antigen Presentation by Melanoma Cells

Journal of Immunotherapy

Volumn 19, Issue 6, 1996, Pages 387-397

  Brady, Mary S ^a   Eckels, David D ^b   Ree, Sophia Y ^a   Schultheiss, Kim E ^a   Lee, Janet S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Antigen presentation; CD54; CD80; CD86; CTLA 4Ig; Human; Melanoma; MHC class II

Indexed keywords

B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD28; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MELANOMA; MOLECULAR SEQUENCE DATA; PEPTIDES; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030322347     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199611000-00001     Document Type: Article

References (54)

1. Radka SF, Charron DJ, Brodsky FM. Review: Class II molecules of the major histocompatibility complex considered as differentiation markers. Hum Immunol 1986;16:390-400.
2. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993;14:491-9.
3. Noelle R, Krammer PH, Ohara J, Uhr JW, Vitetta ES. Increased expression of Ia antigens on resting B cells: an additional role of B-cell growth factor. Proc Natl Acad Sci USA 1984;81:6149-53.
4. Roehme NW, Leibson HJ, Zlotnik A, Kappler J, Marrack P, Cambier JC. Interleukin-induced increase in Ia expression by normal mouse B cells. J Exp Med 1984;160:679-94.
5. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
6. Malnati MS, Marti M, La Vaute T, et al. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature 1992;357:702-41.
7. Brooks A, Hartley S, Kjer-Nielsen L, et al. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc Natl Acad Sci USA 1991; 88:3290-4.
8. Nuchtern JG, Biddo WE, Klausner RD. Class II MHC molecules can use the endogenous pathways of antigen presentation. Nature 1990;343:74-6.
9. Winchester RJ, Yang C-Y, Gibofsky A, Kunkel HG, Lloyd KO, Old LJ. Expression of Ia-like antigens on cultured human malignant melanoma cell lines. Proc Natl Acad Sci USA 1978;75: 6235-9.
10. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S. DR (Ia-like) antigens on human melanoma cells: serologic detection and immunochemical characterization. J Exp Med 1979;149:658-68.
11. Fossati G, Anichini A, Taramelli D, et al. Immune response to autologous human melanoma: implication of class I and II MHC products. Biochem Biophys Acta 1986;865:235-51.
12. Strohal R, Marberger K, Pehamberger H, Stingl G. Immunohistological analysis of anti-melanoma host response. Arch Dermatol Res 1994;287:28-35.
13. Jenkins MK, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 1988;140:3324-30.
14. Alexander MA, Bennicelli J, Guerry D IV. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early disease. J Immunol 1989;142:4070-8.
15. Becker JC, Brabletz T, Czerny C, Termeer C, Brocker EB. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II + melanoma. Int Immunol 1993;5:1501-8.
16. Gaspari AA, Jenkins MK, Katz SI. Class II MHC-bearing keratinocytes induce antigen-specific unresponsiveness in haptenspecific TH1 clones. J Immunol 1988;141:2216-20.
17. Bal V, McIndoe A, Denton G, et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990;20:1893-7.
18. Carey TE, Takahashi T, Resnik LA, Oettgen HF, Old LJ. Cell surface antigens of human and malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 1976;73:3278-82.
19. Barnstable CJ, Bodmer WF, Brown G, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978;14: 9-20.
20. Lamb JR, Eckels DD, Lake P, Woody JN, Green N. Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature 1982;300:66-9.
21. Rosen-Bronson S, Johnson AH, Hartzman RJ, Eckels DD. Human allospecific TLCs generated against HLA antigens associated with DR1 through DRw8. Immunogenetics 1986;23:368-78.
22. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol 1980;125:293-9.
23. Linsley PS, Brady W, Urnes W, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor of the B cell activation antigen B7. J Exp Med 1991;174:561-9.
24. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-11.
25. Freeman GJ, Borriello F, Hodes RJ, et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993;262:907-9.
26. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
27. van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand CD54 provides an important costimulatory signal for the T cell receptor-mediated activation of resting T cells. J Immunol 1990;144:4579-86.
28. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler L, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992;360:266-8.
29. Moretti S, Massobrio R, Brogelli L, Novelli M, Giannotti B, Bernengo MG. Ki67 antigen expression correlates with tumor progression and MHC-DR antigen expression in melanocytic lesions. J Invest Dermatol 1990;95:320-4.
30. van Vreeswijk H, Ruiter DJ, Brocker E-B, Welvaart K, Ferrone S. Differential expression in HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol 1988;90:755-60.
31. Ruiter DJ, Bergman W, Welvaart K, et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984;44:3930-5.
32. Zaloudik J, Moore M, Ghosh AK, Mechl A, Rejthar A. DNA content and MHC class II antigen expression in malignant melanoma: clinical course. J Clin Pathol 1988;41:1078-84.
33. van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988;48:1019-25.
34. Brocker EB, Suter L, Sorg C. HLA-DR expression in primary melanoma of the skin. J Invest Dermatol 1984;82:244-7.
35. Olsen AC, Possum B, Kirkin AF, Zeuthen J, Gaudernack G. A human melanoma cell line, recognized by both MHC class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand J Immunol 1995;41:357-64.
36. Van den Eynde B, Lethé B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991;173:1373-84.
37. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
38. Coulie PG, Weynants P, Lehmann F, et al. Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother 1993;14:104-9.
39. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91: 9461-5.
40. Baskar S, Azarenko V, Marshall EG, Hughes E, Ostrand-Rosenberg S. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol 1994;155:123-33.
41. Baskar S, Nabavi N, Glimcher LH, Ostrand-Rosenberg S. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J Immunother 1993;14:209-15.
42. Chen PW, Ananthaswamy HN. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 1993;151: 244-55.
43. Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 1994;6:741-5.
44. Busch R, Vturina IY, Drexler J, Momburg F, Hammerling GJ. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain. Eur J Immunol 1995;25:48-53.
45. Croft M. Activation of naive, memory and effector T cells. Curr Opin Immunol 1994;6:431-7.
46. Luqman M, Bottomly K. Activation requirements for CD4+ T cells differing in CD45R expression. J Immunol 1992;149:2300-6.
47. Hersey P, Si Z, Smith MJ, Thomas WD. Expression of the costimulatory molecule B7 on melanoma cells. Int J Cancer 1994; 58:527-32.
48. Freeman GJ, Gray GS, Gimmi CD, et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991;174: 625-31.
49. Razi-Wolf Z, Freeman GF, Galvin F, Benacerraf B, Nadler L, Reiser H. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci USA 1992;89:4210-4.
50. Larsen CP, Ritchie SC, Pearson TC, Linsley PS, Lowry RP. Functional expression of the costimulatory molecules, B7/BB1, on murine dendritic cell populations. J Exp Med 1992;176:1215-20.
51. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 1989;86:641-4.
52. Holzmann B, Brocker EB, Lehmann JM, et al. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 1987;39:466-71.
53. Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule I in primary and metastatic melanoma lesions. Cancer Res 1990;50:1271-8.
54. Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ. Surface antigens of melanoma and melanocytes. J Exp Med 1984;160: 255-69.